NHLBI/HCFA Lung Volume Reduction Surgery Study Participants Announced

December 20, 1996

The National Heart, Lung, and Blood Institute (NHLBI) and the Health Care Financing Administration (HCFA) today announced the selection of the 18 medical centers and the data coordinating center that will conduct the first multi-center clinical trial of lung volume reduction surgery (LVRS). (The list of centers is attached.)

The LVRS study is designed to show whether lung volume reduction surgery is a safe and effective procedure for patients in the last stages of emphysema, a chronic lung condition usually caused by smoking that is a major cause of death and disability in the United States. The procedure involves surgical removal of about 20 to 30 percent of each lung.

The study will be conducted by the NHLBI, and HCFA will cover the patient care costs for the Medicare beneficiaries who participate.

"We are pleased to be working with HCFA on this study," said NHLBI Director Dr. Claude Lenfant. "For although LVRS has been reported to improve lung function and quality of life in some cases, there still are many questions about its benefits and risks that should be answered before it is used widely. This study should provide the answers to these questions."

"We need to know whether Medicare should cover this procedure," said HCFA Administrator Bruce C. Vladeck. "The LVRS study should provide the data that we need to determine whether it is effective. And we hope the study will be a model for future collaborations between HCFA and NIH."

As a first step, a registry of all emphysema patients referred to the participating medical centers will be created. Approximately 2,600 patients from the registry who meet specific inclusion criteria will be invited to participate in the randomized trial. All participants in the trial will receive intensive medical therapy and rehabilitation. Half will also be selected randomly to undergo LVRS. It is expected that the first patients will be enrolled in the registry starting late in the summer of 1997, and enrollment will continue at least until the summer of 1999.

All participants will be evaluated for exercise ability, lung function, quality of life, illness and survival, and the results for the patients who underwent LVRS will be compared with those for the other patients. Although it has been estimated that it will take seven years to complete the study, treatment recommendations may be made sooner than that if the data, which are reviewed every three months by an independent panel of experts, show clear-cut benefits or risks.

The decision to undertake the study grew out of two independent assessments. One, an NHLBI workshop of medical experts, held in September 1995, recommended that systematic evaluation of long-term outcomes of LVRS and of patient selection criteria was urgently needed before the procedure became more widely practiced. A separate, but simultaneous, assessment of the procedure, conducted for HCFA by the federal Agency for Health Care Policy and Research, found that the current data on the risks and benefits of LVRS were too inconclusive to justify unrestricted Medicare reimbursement for the procedure. A clinical trial evaluating the effectiveness of the surgery was recommended. In April 1996, the NHLBI and HCFA announced that they would collaborate on the study.

Approximately 2 million Americans, most of them over age 50, have been diagnosed with emphysema. Current treatment for patients in the end stages of emphysema is largely supportive, including nutritional supplementation and exercise rehabilitation. Lung transplantation may be an option for some patients under age 60, but donor lungs are scarce, and the procedure is expensive. The LVRS study will show whether this procedure can provide another treatment option for some of these patients.

NOTE: People with emphysema who want to participate in the study should discuss this with their doctors and ask for a referral to one of the participating centers, or call the patient coordinator at the nearest participating center.

NHLBI press releases, fact sheets, and other materials are available on the Internet via the NHLBI home page at http://www.nhlbi.nih.gov/nhlbi/nhlbi.htm


Clinical Centers

Cleveland Clinic Foundation
Cleveland, OH
Principal Investigator: Janet R. Maurer, MD
Patient Referral: 1-800-822-9488
Other Information: Barbara Higgins, RN
1-800-223-2273, Ext. 54215 of 216-445-4215

University of California, San Diego Medical Center
San Diego, CA
Principal Investigator: Andrew Ries, MD
Patient Referral: Trina Limberg

University of Michigan
Ann Arbor, MI
Principal Investigator: Fernando J. Martinez, MD
Patient Referral: Telecare, 800-742-2300 Routing #6235
Other Information: Pamela Lewis, RN

Temple University
Philadelphia, PA
Principal Investigator: Gerard J. Criner, MD
Patient Referral: Anne Marie Kuzma, RN

Cedars-Sinai Medical Center
Los Angeles, CA
Principal Investigator: Robert McKenna, MD
Patient Information: Brenda Williams
1-800-CEDARS-1 or Fax 310-854-3917
Other Information: Zab Mohsenifar, MD, Principal Investigator
310-855-4685 or Fax 310-967-0129

Ohio State University
Columbus, OH
Principal Investigator: Philip T. Diaz, MD
Patient Referral: Mary Lou Coffee

University of Pittsburgh
Pittsburgh, PA
Principal Investigator: Robert J. Keenan, MD
Patient Referral: Betsy George, RN

Columbia-Presbyterian Medical Center/
Long Island Jewish Center
New York, NY
Principal Investigator: Mark Ginsburg, MD
Patient Referral:
Patricia A. Jellen, MSN, RNC, 212-305-1158
Kerry McKeon, RN, 718-470-4200

National Jewish Center for Immunology and Respiratory Medicine
Denver, CO
Principal Investigator: Reuben M. Cherniack, MD
Patient Referral: Lung Line, 1-800-222-LUNG
Other Information: Physician Referral Line

Washington University
St. Louis, MO
Principal Investigator: Joel D. Cooper, MD
Patient Referral: Deen Scharff

Brigham & Women's Hospital
Boston, MA
Principal Investigator: John J. Reilly, MD
Patient Referral: Tammy Weihrauch
1-888-BWH-LUNG (1-888-294-5864)

Baylor College of Medicine
Houston, TX
Principal Investigator: Rafael Espada, MD
Patient Referral: Charles Miller

Duke University Medical Center
Durham, NC
Principal Investigator: Neil R. MacIntyre, MD
Patient Referral: Janet Johns

Mayo Clinic
Rochester, MN
Principal Investigator: Rolf D. Hubmayr, MD
Patient Referral: Kristin A. Bradt

University of Maryland at Baltimore
Baltimore, MD
Principal Investigator: Mark J. Krasna, MD
Patient Referral: Karen King, RN

University of Pennsylvania Medical Center
Philadelphia, PA
Principal Investigator: Larry Kaiser, MD
Patient Referral: Penn Health Customer Service

University of Washington
Seattle, WA
Principal Investigator: Richard K. Albert, MD
Patient Referral: Doctors, Inc.

Saint Louis University
St. Louis, MO
Principal Investigator: Keith S. Naunheim, MD
Patient Referral: Gina Roelke
Other Information: Laura Taylor Bianchi

Coordinating Center

The Johns Hopkins University
Baltimore, MD
Principal Investigator: Steven Piantadosi, MD

NIH/National Heart, Lung and Blood Institute

Related Emphysema Articles from Brightsurf:

Lung-specific risk factors may increase hip fracture risk in individuals who smoke
Smoking has been linked to a higher risk of bone fractures.

A targeted treatment for emphysema?
Emphysema is a progressive, debilitating lung disease in which the lung's breathing sacs, or alveoli, enlarge, get thinner, and eventually are destroyed as the cells die off.

E-cigs can trigger same lung changes seen in smokers, emphysema
In a study published in the American Journal of Respiratory and Critical Care Medicine, the UNC scientists found that the lungs of vapers -- like the lungs of smokers -- have elevated levels of protease enzymes, a condition known to cause emphysema in smokers.

Exposure to outdoor air pollutants, change in emphysema, lung function
Whether exposure to outdoor air pollutants is associated with emphysema progression and change in lung function was the focus of this observational study.

Study finds link between long-term exposure to air pollution and emphysema
Long-term exposure to air pollution was linked to increases in emphysema between 2000 and 2018, according to a new study funded by the National Institute of Environmental Health Sciences (NIEHS) and the National Heart, Lung, and Blood Institute (NHLBI), both part of the National Institutes of Health.

Pollutant linked to climate change accelerates lung disease
A new multicenter study at Columbia University links long-term exposure to air pollution, especially ozone, to development of emphysema, accelerating lung disease progression as much as a pack a day of cigarettes.

Piedmont Atlanta first in Georgia to offer new minimally invasive treatment for emphysema
Piedmont Atlanta Hospital is the first in the state of Georgia to offer a new minimally invasive treatment for emphysema, a severe form of Chronic Obstructive Pulmonary Disease (COPD).

MedStar Franklin Square to offer new treatment option for qualified emphysema patients
MedStar Franklin Square is the first medical facility in the state to offer endoscopic lung volume reduction (ELVR), using a new FDA-approved lung valve that is positioned in damaged lung airways without surgery, and allows patients with severe emphysema to breathe easier.

Protein may slow progression of emphysema, Rutgers study finds
A protein generated as part of our body's immune response to intestinal worms could slow the progression of emphysema, according to a Rutgers study.

Temple Lung Center director reports ongoing positive results for emphysema treatment study
Dr. Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University, announced the 12-month results of the EMPROVE multicenter, randomized and controlled study for the Spiration® Valve System (SVS), a minimally invasive treatment for severe emphysema, at the European Respiratory Society International Congress (ERS) in Paris, France, on Sept.

Read More: Emphysema News and Emphysema Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.